Eledon Pharmaceuticals, Inc. ELDN
Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) is an immunology/inflammation drug developer. Its lead program, tegoprubart, is in Phase 2 for Prevention of allograft rejection in kidney transplantation. Its next catalyst on record is tegoprubart (kidney transplant): Initiation of Phase 3 clinical development (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: tegoprubart (kidney transplant) — Initiation of Phase 3 clinical development (H2 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| tegoprubart | Kidney transplant rejection prevention (Phase 2 BESTOW complete, long-term extension ongoing; Phase 1b ongoing) | antibody | Phase 2 |
| tegoprubart | Islet cell transplantation (investigator-initiated trial, University of Chicago) | antibody | Phase 2 |
| tegoprubart | ALS (Phase 2a completed May 2022; development paused absent funding) | antibody | Phase 2 |
| tegoprubart | Xenotransplantation (compassionate/collaborative use with eGenesis) | antibody | Phase 1 |
| tegoprubart | Liver transplantation | antibody | Pre-clinical |
Recent results and decisions
- Nov 6, 2025missed Phase 2 BESTOW did not reach statistical significance on the primary endpoint of 12-month eGFR change (69 vs 66 mL/min/1.73 m2, tegoprubart vs tacrolimus); efficacy-failure composite 22% vs 17% was non-inferior on a 20% margin and biopsy-proven acute rejection was 20.6% vs 14.1%.
Although the primary endpoint did not reach statistical significance, tegoprubart maintained strong renal function, delivering what the Company believes is the highest mean eGFR level reported to date in kidney transplant clinical trials evaluating rejection prevention.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.